Expand JAGX Menu
JAGX MENU

JAGX Latest Press Releases

-- December 12, 2024 --

Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS) ACCESSWIRE 9:01 AM

-- December 9, 2024 --

Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS) ACCESSWIRE 10:01 AM

-- December 6, 2024 --

U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins ACCESSWIRE 8:30 AM

-- December 5, 2024 --

Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine ACCESSWIRE 12:01 PM

-- December 4, 2024 --

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now Globe Newswire 7:00 AM

-- December 3, 2024 --

Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now Globe Newswire 7:00 AM

-- December 2, 2024 --

Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs ACCESSWIRE 10:13 AM

-- November 25, 2024 --

Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference ACCESSWIRE 10:01 AM

-- November 22, 2024 --

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs ACCESSWIRE 8:46 AM

-- November 19, 2024 --

Jaguar Health Family Company Napo Therapeutics Named "Best Pharmaceuticals Innovator of the Year - Europe" ACCESSWIRE 9:31 AM

-- November 13, 2024 --

Jaguar Health Reports Third Quarter 2024 Financial Results ACCESSWIRE 8:01 AM

-- November 11, 2024 --

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates ACCESSWIRE 8:31 AM

-- November 6, 2024 --

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs ACCESSWIRE 10:11 AM

-- November 4, 2024 --

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS) ACCESSWIRE 8:32 AM

-- October 29, 2024 --

Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting ACCESSWIRE 10:03 AM

-- October 16, 2024 --

Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S. ACCESSWIRE 8:31 AM

-- October 11, 2024 --

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ACCESSWIRE 4:18 PM

-- October 10, 2024 --

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum ACCESSWIRE 10:01 AM

-- October 8, 2024 --

Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial ACCESSWIRE 8:31 AM

-- October 1, 2024 --

Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer ACCESSWIRE 8:33 AM

-- September 26, 2024 --

Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Survivors ACCESSWIRE 4:48 PM

-- September 25, 2024 --

Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 ACCESSWIRE 8:32 AM

-- September 24, 2024 --

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch ACCESSWIRE 10:03 AM

-- September 16, 2024 --

Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference ACCESSWIRE 10:03 AM

-- September 10, 2024 --

Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care ACCESSWIRE 10:04 AM

-- September 6, 2024 --

Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference ACCESSWIRE 10:01 AM

-- September 5, 2024 --

Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs ACCESSWIRE 8:33 AM

-- September 4, 2024 --

New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company's Near-Term Commercial & Development Milestones ACCESSWIRE 10:05 AM

-- August 27, 2024 --

Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) ACCESSWIRE 10:21 AM

-- August 20, 2024 --

Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award ACCESSWIRE 10:02 AM

-- August 19, 2024 --

Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) ACCESSWIRE 10:03 AM

-- August 13, 2024 --

Jaguar Health Reports Second Quarter 2024 Financial Results ACCESSWIRE 8:02 AM

-- August 5, 2024 --

Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial's Clinically Meaningful Results ACCESSWIRE 10:19 AM

-- August 2, 2024 --

Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy ACCESSWIRE 10:02 AM

-- August 1, 2024 --

Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting ACCESSWIRE 9:11 AM

-- July 31, 2024 --

Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs) ACCESSWIRE 10:03 AM

-- July 23, 2024 --

Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer ACCESSWIRE 1:23 PM

-- July 18, 2024 --

Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning ACCESSWIRE 10:31 AM